Aprea Therapeutics (NASDAQ:APRE) Trading Up 2.8% – Time to Buy?

Aprea Therapeutics, Inc. (NASDAQ:APRE)’s share price was up 2.8% on Thursday . The company traded as high as $0.8071 and last traded at $0.7830. Approximately 51,910 shares were traded during trading, a decline of 74% from the average daily volume of 196,794 shares. The stock had previously closed at $0.7620.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Wedbush lowered their target price on Aprea Therapeutics from $7.00 to $6.00 and set an “outperform” rating for the company in a report on Thursday, May 14th. Weiss Ratings restated a “sell (e+)” rating on shares of Aprea Therapeutics in a report on Monday, April 20th. Zacks Research upgraded Aprea Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, February 16th. HC Wainwright lowered their target price on Aprea Therapeutics from $4.00 to $1.20 and set a “buy” rating for the company in a report on Tuesday, March 31st. Finally, Oppenheimer assumed coverage on Aprea Therapeutics in a report on Thursday, May 7th. They set an “outperform” rating and a $5.00 target price for the company. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Aprea Therapeutics presently has an average rating of “Hold” and a consensus target price of $4.07.

Aprea Therapeutics Price Performance

The business has a fifty day simple moving average of $0.85 and a two-hundred day simple moving average of $0.87. The company has a market cap of $9.18 million, a PE ratio of -0.48 and a beta of 1.51.

Aprea Therapeutics (NASDAQ:APRE) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.01. The firm had revenue of $0.28 million during the quarter, compared to analyst estimates of $0.00 million. Aprea Therapeutics had a negative return on equity of 61.03% and a negative net margin of 4,405.59%. On average, equities research analysts predict that Aprea Therapeutics, Inc. will post -0.83 EPS for the current year.

Institutional Trading of Aprea Therapeutics

Institutional investors have recently made changes to their positions in the business. Jane Street Group LLC acquired a new stake in shares of Aprea Therapeutics in the 4th quarter worth $40,000. DRW Securities LLC acquired a new stake in shares of Aprea Therapeutics in the 4th quarter worth $103,000. Finally, AIGH Capital Management LLC boosted its position in shares of Aprea Therapeutics by 174.1% in the 1st quarter. AIGH Capital Management LLC now owns 1,015,541 shares of the company’s stock worth $775,000 after purchasing an additional 645,000 shares in the last quarter. Institutional investors and hedge funds own 34.19% of the company’s stock.

Aprea Therapeutics Company Profile

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.